Comparison · NCT00687713-sae
Bupropion vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Bupropion vs Placebo: serious adverse events. Trial comparisons, record NCT00687713-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00687713-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.01 | 0.00177 | 0.0545 | wilson | |
| Risk in group 2 | 0.0288 | 0.00986 | 0.0814 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0188 | -0.072 | 0.0295 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.347 | 0.0367 | 3.28 | log | |
| Odds ratio, group 1 over group 2 | 0.34 | 0.0348 | 3.33 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Bupropion than on Placebo | 53.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Bupropion | Subjects received bupropion 150 mg tablet for 3 days then twice daily, for 12 weeks until dose taper during the last 3 days of week 12 at 150 mg per day.~Bupropion: 150mg for the first 3 days of dosing. Increased to 150 mg b.i.d until taper. | 1 | 100 | EG000 |
| Group 2 | Placebo | Subjects received a matched bupropion placebo 150 mg tablet for 3 days then twice daily, for 12 weeks until dose taper during the last 3 days of week 12 at 150 mg per day.~Placebo: Placebo | 3 | 104 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence
- NCT number
- NCT00687713
- Phases
- PHASE2
- Conditions
- Methamphetamine Dependence
- Interventions
- Bupropion, Placebo
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- Results first posted
- 2017-02-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00687713?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00687713-sae